N/A
Completed N=3,400
Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism
Source: ClinicalTrials.gov NCT00523614 ↗Enrolled (actual)
3,400
Serious AEs
0.0%
Results posted
Dec 2009
Primary outcomePrimary: Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC) — 35; 106; 161; 423 Participants — p=<0.05
Summary
The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral contraceptives with non-use, focusing specifically on Valette® compared to other users of low estrogen dose combined oral contraceptives.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Risk of Venous Thromboembolism (VTE) Between Women Who Use Dienogest/Ethinylestradiol (DNG/EE) and Women Who Use Other Low-dose Combined Oral Contraceptives (COC) |
35; 106; 161; 423 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- cases: women with a venous thromboembolism who are between 15 and 49 years old
- control: women without a venous thromboembolism diagnosis who are between 15 and 49 years old
Exclusion Criteria
- women outside the defined age range
- women with severe language problems
- women who are not willing to participate
Data sourced from ClinicalTrials.gov (NCT00523614). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.